Share Email Print

Proceedings Paper

SERS detection and targeted ablation of lymphoma cells using functionalized Ag nanoparticles
Author(s): Qian Yao; Fei Cao; Chao Feng; Yan Zhao; Xiuhong Wang
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Lymphoma is a heterogeneous group of malignancies of the lymphoid tissue, and is prevalent worldwide affecting both children and adults with a high mortality rate. There is in dire need of accurate and noninvasive approaches for early detection of the disease. Herein, we report a facile way to fabricate silver nanoparticle based nanoprobe by incorporating the corner-stone immunotherapeutic drug Rituxan for simultaneous detection and ablation of lymphoma cells in vitro. The fabricated nanoprobe can detect CD20 positive single lymphoma cell by surface enhanced Raman scattering technique with high specificity. The engineered nanoprobe retains the same antibody property as intact drug via Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) analysis. The nanoprobe efficiently eradicates lymphoma cells in vitro. By integrating the advantages of sensitive SERS detection with targeted ablation capabilities of immunotherapeutic drug through site specificity, this nanoprobe can be applied as outstanding tools in living imaging, cancer diagnosis and treatment.

Paper Details

Date Published: 22 April 2016
PDF: 9 pages
Proc. SPIE 9724, Plasmonics in Biology and Medicine XIII, 972407 (22 April 2016); doi: 10.1117/12.2212285
Show Author Affiliations
Qian Yao, Beijing Univ. of Technology (China)
Fei Cao, Beijing Univ. of Technology (China)
Chao Feng, Beijing Univ. of Technology (China)
Yan Zhao, Beijing Univ. of Technology (China)
Xiuhong Wang, Beijing Univ. of Technology (China)

Published in SPIE Proceedings Vol. 9724:
Plasmonics in Biology and Medicine XIII
Tuan Vo-Dinh; Joseph R. Lakowicz, Editor(s)

© SPIE. Terms of Use
Back to Top